[go: up one dir, main page]

AR006345A1 - Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion. - Google Patents

Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion.

Info

Publication number
AR006345A1
AR006345A1 ARP970101146A ARP970101146A AR006345A1 AR 006345 A1 AR006345 A1 AR 006345A1 AR P970101146 A ARP970101146 A AR P970101146A AR P970101146 A ARP970101146 A AR P970101146A AR 006345 A1 AR006345 A1 AR 006345A1
Authority
AR
Argentina
Prior art keywords
composition
hiv protease
water
protease inhibitor
derivative
Prior art date
Application number
ARP970101146A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR006345A1 publication Critical patent/AR006345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a composiciones farmacéutica que contienen los inhibidores de proteasa del VIH, que incluyen específicamente el éster tetrahidro-3-furanílicodel ácido 3S-[3R*(1R*,2S*)]-3-[[(4-aminofenil)sulfonil](2-metilpropil)-amino] -2-hidroxi-]-fenilmetil)-propil]carbámico (conocido alternativamente comoVX 478 o 141W94), y un tocoferol, y a su uso en terapia médica. Las composiciones pueden ser preparadas disolviendo un inhibidor de proteasa delVIH en un derivado del tocoferolsol uble en agua.
ARP970101146A 1996-03-22 1997-03-21 Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion. AR006345A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
AR006345A1 true AR006345A1 (es) 1999-08-25

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101146A AR006345A1 (es) 1996-03-22 1997-03-21 Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion.

Country Status (12)

Country Link
JP (1) JP3117726B2 (es)
AR (1) AR006345A1 (es)
BG (1) BG64457B1 (es)
CO (1) CO4790151A1 (es)
HU (1) HU228026B1 (es)
ID (1) ID16781A (es)
IL (1) IL126185A (es)
MY (1) MY126358A (es)
OA (1) OA10880A (es)
PL (1) PL187919B1 (es)
TW (1) TW455491B (es)
WO (1) WO1997035587A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017366A4 (en) * 1996-09-01 2006-03-22 Pharmos Corp SOLID COPARCIPITATES FOR IMPROVED BIOVERABILITY OF LIPOPHILIC SUBSTANCES
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (es) * 1997-12-04 2000-10-16 Univ Granada Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
EP1354587A1 (en) * 2000-12-22 2003-10-22 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JP2006518380A (ja) 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション 固体分散体組成物
US20060068007A1 (en) * 2004-09-24 2006-03-30 Boehringer Ingelheim Pharmaceuticals, Inc. Class of surfactant-like materials
CN101031284A (zh) * 2004-09-30 2007-09-05 伊斯曼化学公司 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1677092A (en) * 1991-03-20 1992-10-21 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
ES2112880T3 (es) * 1991-11-08 1998-04-16 Merck & Co Inc Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ES2189721T3 (es) * 1992-12-29 2003-07-16 Abbott Lab Inhibidores de proteasa retroviral.
US5714518A (en) * 1993-01-15 1998-02-03 Agouron Pharmaceuticals HIV protease inhibitors and methods of making the same
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
CA2178760C (en) * 1993-12-15 2000-08-01 Joel R. Huff Hiv protease inhibitors
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
BG102838A (en) 1999-09-30
JP3117726B2 (ja) 2000-12-18
JP2000500504A (ja) 2000-01-18
HU228026B1 (en) 2012-08-28
BG64457B1 (bg) 2005-03-31
PL328916A1 (en) 1999-03-01
HUP9901887A3 (en) 2000-02-28
TW455491B (en) 2001-09-21
IL126185A (en) 2003-05-29
ID16781A (id) 1997-11-13
CO4790151A1 (es) 1999-05-31
MY126358A (en) 2006-09-29
PL187919B1 (pl) 2004-11-30
IL126185A0 (en) 1999-05-09
HUP9901887A2 (hu) 1999-12-28
WO1997035587A1 (en) 1997-10-02
OA10880A (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR006345A1 (es) Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2233931T3 (es) Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
MX9306708A (es) Composiciones de espuma de lucha contra el fuego, de un solvente polar de baja viscosidad.
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
ES2113444T3 (es) Medicamentos.
BR9714310A (pt) Composição farmacêutica
AR033688A1 (es) Composicion parenteral reconstituible
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
ES2192349T3 (es) Derivados alfa-hidroxi, amino y halo de acidos hidroxamicos beta-sulfonilo utilizados como inhibidores de metaloproteinas matriciales.
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
ES2173883T3 (es) Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
ES2091183T3 (es) Metodo para mejorar el sueño.

Legal Events

Date Code Title Description
FG Grant, registration